ArticlePediatric cardiology2026
Abnormal Cardiac Magnetic Resonance Imaging Mapping Parameters in Pediatric Heart Transplant Patients with Elevated Donor-Derived Cell Free DNA.
Article in Pediatric cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Heart transplant (HT) rejection surveillance is rapidly evolving with evidence supporting use of donor-derived cellfree DNA (ddcfDNA) with its high negative predictive value and use of cardiac magnetic resonance (CMR). Both modalities are imperfect in diagnosing biopsy proven rejection, however, combining them may improve diagnostic power. Our study goal is to characterize multiparametric CMR trends between pediatric HT patients (PHT) with high versus low ddcfDNA. Single center retrospective study of PHT who had clinically indicated multiparametric CMR (biventricular volumes and ejection fraction (EF), T2 mapping, T1 mapping with extracellular volume fraction (ECV) and ddcfDNA within 30 days; corresponding EMB was not always performed as per institutional clinical protocol. Demographics and CMR variables were compared between ddcfDNA of ≥ 0.16% (high group) and < 0.16% (low group). 68 PHT (14 high group, 54 low group) were included. The high group was significantly older, with longer time between CMR and HT, had longer time between CMR and ddcfDNA, had more frequent CMR indication of clinical concern and had history of CAV or moderate severe rejection. No statistical difference in CMR derived ventricular volumes or function was noted between groups. There were significant differences in multiparametric mapping with high ddcfDNA group showing higher global T1 (1086 [1050, 1118] vs. 1029 [1002, 1075] ms; p = 0.01), peak segmental T1 (1163 [1140, 1220] vs. 1121 [1056, 1175] ms; p = 0.04), global T2 (52 [50, 55] vs. 48 [46, 51] ms; p = 0.008), and peak segmental T2 (58 [54, 60] vs. 53 [51, 59] ms; p = 0.04) compared to the low ddcfDNA group respectively. Multiparametric CMR suggests graft structure differences between high and low ddcfDNA PHT. Studies on larger cohorts with wider ddcfDNA ranges can help understand the combined role of CMR and ddcfDNA in improving surveillance.
Indexed as
Identifiers
42423982What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.